Thrombocytopenia and Lupus-Like Anticoagulant in a Patient with Peripheral Vascular Disease: Response to Infusion of Prostacyclin

Abstract

A 46 year old man with intermittent claudication due to severe peripheral vascular disease had a circulating lupus like anticoagulant (LLAC), thrombocy topenia (79 x 10⁹/₁), markedly reduced platelet survival and a normal bone mar row. He was treated with intravenous prostacyclin (PGI₂) infusions which resulted in improvement of the patient's exercise tolerance and normalisation of his platelet count (300 x 10⁹/₁) and platelet aggregation could then be assessed. The platelets were markedly hyperaggregable and generated supranormal quantities of thromboxane A₂. A diagnosis of consumptive thrombocytopenia secondary to peripheral vascular disease and platelet hyperaggregability was made. Despite therapy with aspirin and dipyridamole, gradual and progressive reduction in platelet count followed and his exercise tolerance declined over the next three months. Immunoglobulin prepared from the patient's serum did not inhibit vascular PGI₂ synthesis in vitro.

To our knowledge this is the first reported case of consumptive thrombocyto penia due to severe peripheral vascular disease and platelet hyperaggregability. PGI₂ administration caused a transient resolution of these features which was not sustained by aspirin and dipyridamole.

Get full access to this article

View all access options for this article.

References

Lowe Gdo : Laboratory evaluation of hypercoagulability. In: Clinics in Haematology Vol. 10-Thrombosis. Ed. by Prentice CRM. London , WB Saunders, 1981, pp. 407-442.

Sinzinger H. , Horsch AK , Silberbauer K. : The behaviour of various platelet function tests during long-term prostacycin infusion in patients with peripheral vascular disease. Thromb Haem 50: 885-887, 1983.

Mikhailidis DP , Barradas MA , Jeremy JY , et al: Endogenous platelet thromboxane A 2 production in diabetic patients with and without peripheral vascular disease. Diabetologia 25: 180-181, 1983.

Harker LA , Schwartz SM , Ross R. : Endothelium and arteriosclerosis. In: Clinics in Haematology Vol. 10-Thrombosis. Ed. by Prentice CRM. London, WB Saunders, 1981, pp. 283-296.

Boey ML , Cloaco CB , Gharavi AE , et al: Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Br Med J 287: 1021-1023, 1983.

Hughes Grv : Thrombosis, abortion, cerebral disease and the lupus anticoagulant. Br Med J 287: 1088-1089, 1983.

Carreras CO , Defreyn G. , Machin SJ , et al: Arterial thrombosis, intrauterine death and "lupus" anticoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet i: 244-246, 1981.

Mikhailidis DP , Jeremy JY , Barradas MA , et al: The effect of ethanol on vascular prostacyclin synthesis, platelet aggregation and platelet thromboxane release . Br Med J 287: 1495-1498, 1983 .

Khokher MA , Dandona P. : Insulin-like stimulatory effect of Fc fragments of human immunoglobulin G on rat adipocyte lipogenesis: indirect evidence for Fc receptors on adipocytes . J Clin Endocrinol Metab 56: 393-396, 1983.

10.

Jeremy JY , Mikhailidis DP , Dandona P. : Vascular trauma and prostacyclin release. Microcircul Endothel Lymph 1: 629-644, 1984.

11.

De Gaetano G. : Platelets, prostaglandins and thrombotic disorders . In: Clinics in Haematology Vol. 10-Thrombosis. Ed. by Prentice CRM. London, WB Saunders, 1981, pp. 297-326.

12.

Meade TW : Risk associations in the thrombotic disorders. In: Clinics in Haematology Vol 10-Thrombosis. Ed. by Prentice CRM. London, WB Saunders , 1981, pp. 391-405.

13.

Reele SB , Miller OV , Spillers C. , Gorman RR : The effects of continuous infusions of prostacyclin-Na on platelet counts, ADP-induced platelet aggregation and cyclic-AMP levels in normal volunteers . Prostaglandins 26: 287-302, 1983.

14.

Jeremy JY , Mikhailidis DP , Dandona P. : Stimulating the environment modifies in vitro prostacyclin synthesis. Diabetes 32: 217-221, 1983.

15.

Mikhailidis DP , Mikhailidis AM , Barradas MA , Dandona P. : Effect of non-esterified fatty acids on the stability of prostacyclin activity. Metabolism 32: 717-721, 1983.